Novo Nordisk secures early patent win in Netherlands

A Dutch lower court has granted Novo Nordisk a court order against Cipan Zikenhauso Pharmacia, including an injunction to cease all activities that infringe on the patent for the active substance semaglutide, used in the Wegovy weight loss treatment. The court ordered the removal of listings for infringing products, the disclosure of supply chain information, and the payment of legal costs. This reflects Novo Nordisk's efforts to protect its intellectual property rights from infringements across the European market, even as patents in some other markets are waning, opening the door for other companies to produce generic versions of the drug. These measures are expected to strengthen Novo Nordisk’s patent protections and reduce costs for patients.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل